Ipamorelin vs. GHRP-6: Comparative Analysis of GH Secretagogues

Growth-hormone-releasing peptides (GHRPs) are a class of synthetic ghrelin-receptor agonists that stimulate endogenous growth hormone (GH) release from the anterior pituitary. Within this class, Ipamorelin and GHRP-6 are among the most extensively researched compounds and are routinely compared in the published literature on GH secretagogue pharmacology. This meta-analysis synthesises results from twenty-eight clinical and preclinical investigations published between 1995 and 2023 that directly contrast the two peptides on three primary axes: GH-release potency and selectivity, ancillary endocrine effects (notably cortisol, prolactin, and acylated ghrelin response), and side-effect profile in human research subjects. Both peptides bind the growth-hormone secretagogue receptor (GHS-R1a) — the same receptor activated by endogenous ghrelin — and trigger pulsatile GH release that broadly mimics the natural circadian secretion pattern. However, their pharmacological profiles differ in clinically relevant ways. Ipamorelin, a pentapeptide first reported in 1998, is characterised in the literature as a 'selective' GH secretagogue: across multiple healthy-volunteer dose-response studies, single subcutaneous doses of 10-100 ug/kg produced robust GH peaks (typically 60-90 ng/mL at the higher doses) with no statistically significant elevation of cortisol, ACTH, or prolactin. This selectivity profile is the reason Ipamorelin is frequently described in research-grade literature as a 'cleaner' tool for studying isolated GH-axis biology. GHRP-6, by contrast, is a hexapeptide developed in 1980s and shares the same GHS-R1a binding mechanism but is consistently associated with measurable elevation of cortisol and prolactin alongside GH release in human research subjects. GHRP-6 also produces a strong, dose-dependent stimulation of subjective hunger — an effect attributed to its activation of orexigenic ghrelin signalling pathways in the hypothalamus — which limits its utility in research protocols where appetite confounds are problematic. The meta-analysis groups the twenty-eight included studies by primary outcome. For peak GH release at equivalent molar doses, the pooled effect size favours Ipamorelin marginally for selectivity but the two peptides produce comparable GH AUC over a four-hour post-dose window. For cortisol response, GHRP-6 produces a statistically significant rise (mean +28% above baseline at 30 minutes post-dose) versus essentially flat response with Ipamorelin. For prolactin, the same pattern holds (GHRP-6 +22%, Ipamorelin not significantly different from placebo). For subjective hunger ratings (visual analogue scale), GHRP-6 produces a clear and consistent increase that peaks at 45-60 minutes post-injection, whereas Ipamorelin produces no significant change. The review also examines tachyphylaxis — the well-documented phenomenon whereby continuous GHRP exposure leads to attenuated GH response over time. Both peptides exhibit tachyphylaxis with continuous infusion or frequent repeated dosing, but the kinetics differ: GHRP-6 desensitisation is reported in some studies as more rapid (within 7-10 days of three-times-daily dosing), whereas Ipamorelin appears to retain responsiveness longer in the limited published cohorts examining this question. Combination strategies (CJC-1295 + Ipamorelin or CJC-1295 + GHRP-6) are widely discussed in the secondary literature, though the meta-analysis notes that head-to-head clinical trials of these combinations are sparse and that synergy claims rest predominantly on extrapolation from single-agent pharmacology rather than direct combination data. Safety signals across the included studies are reassuring within tested doses: no serious adverse events were attributed to either peptide in the included clinical investigations, although the analysis is constrained by the short duration of most studies (typically single-dose to 4-week regimens). Long-term safety data — particularly with respect to insulin sensitivity, IGF-1 elevation, and any oncological signal from sustained GH-axis stimulation — remain limited. Both peptides are unscheduled by the FDA for clinical use; neither is approved as a drug for any indication. They are routinely available as research-grade compounds for in-vitro and animal investigation. All discussion is presented for research education and does not constitute medical guidance or endorsement of off-label human use.